OOIR: Observatory of International Research

Papers

(The H4-Index of ERJ Open Research is 32. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome?	504
Benefits of pulmonary rehabilitation in COVID-19: a prospective observational cohort study	123
Pneumomediastinum and subcutaneous emphysema in COVID-19: barotrauma or lung frailty?	95
Chest radiography is a poor predictor of respiratory symptoms and functional impairment in survivors of severe COVID-19 pneumonia	86
D-dimer as an indicator of prognosis in SARS-CoV-2 infection: a systematic review	75
Recovery from COVID-19: a sprint or marathon? 6-month follow-up data from online long COVID-19 support group members	74
Current strategies for managing chronic thromboembolic pulmonary hypertension: results of the worldwide prospective CTEPH Registry	65
Global burden of COVID-19 pandemic on healthcare workers	64
Diagnosis of COVID-19 by exhaled breath analysis using gas chromatography-mass spectrometry	64
Type 2 inflammation in asthma and other airway diseases	61
Prospective longitudinal evaluation of hospitalised COVID-19 survivors 3 and 12 months after discharge	57
Mortality and morbidity in obstructive sleep apnoea–hypopnoea syndrome: results from a 30-year prospective cohort study	57
The role of interleukin-17 in asthma: a protective response?	52
Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients	51
COVID-19 in children with underlying chronic respiratory diseases: survey results from 174 centres	47
Outcomes of COVID-19 patients treated with continuous positive airway pressure outside the intensive care unit	47
COPD in the time of COVID-19: an analysis of acute exacerbations and reported behavioural changes in patients with COPD	45
Descriptive analysis of long COVID sequela identified in a multidisciplinary clinic serving hospitalised and non-hospitalised patients	45
Underestimation of COVID-19 mortality during the pandemic	44
Identification and treatment of T2-low asthma in the era of biologics	43
Prevalence and incidence of, and risk factors for chronic cough in the adult population: the Rotterdam Study	43
Diagnosing COVID-19 pneumonia in a pandemic setting: Lung Ultrasound versus CT (LUVCT) – a multicentre, prospective, observational study	40
COVID-19 in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a reference centre survey	39
Predicting and preventing hospital readmission for exacerbations of COPD	38
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough	37

Evaluation of a multicomponent grading system for obstructive sleep apnoea: the Baveno classification	36
Increased circulating levels of angiotensin-(1–7) in severely ill COVID-19 patients	34
Cognitive behavioural therapy for insomnia reduces sleep apnoea severity: a randomised controlled trial	34
Clinical characteristics, risk factors and outcomes in patients with severe COVID-19 registered in the International Severe Acute Respiratory and Emerging Infection Consortium WHO clinical characteris	33
INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice	33
The burden of exacerbations in mild asthma: a systematic review	33
Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis	32
Shorter telomere length following lung transplantation is associated with clinically significant leukopenia and decreased chronic lung allograft dysfunction-free survival	32